OncoTherapy Science Inc Announces Start of Phase I Clinical Trial of OTS167

OncoTherapy Science Inc announced the start of the phase I clinical trial of OTS167, which is a kind of molecular target drug targeted at kinase Maternal Embryonic Leucine zipper Kinase.

Monday, 1 Jul 2013 08:00pm EDT

Shanghai RAAS Blood Products Co Ltd to Issue New Shares for Acquisition of Company and Fund Raising

Shanghai RAAS Blood Products Co Ltd announced that it has decided to issue a total of 93,652,444 shares, at the price of RMB 19.22 per share, to acquire a 100% stake in Banghe Pharmaceutical Co., Ltd, including 29,191,467 shares to Nanchang-based investment company for a 31.17% stake in Banghe...

Monday, 1 Jul 2013 08:00pm EDT

Pfizer Inc, Novartis AG May Join Amgen In Bidding For Onyx Pharmaceuticals Inc-Reuters

Reuters reported that Onyx Pharmaceuticals Inc whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG. Onyx had rejected a recent $8.7 billion offer from larger biotech Amgen Inc as...

Monday, 1 Jul 2013 06:37pm EDT

FDA Grants Humanitarian Use Device Designation To Circadian Technologies Ltd's VEGF-D Kit

Circadian Technologies Ltd announced that the US FDA has designated its VEGF-D assay kit as a humanitarian use device (HUD), for 'the detection of circulating VEGF-D intended to monitor patients who have been diagnosed with lymphangioleiomyomatosis (LAM) for disease progression and response to...

Monday, 1 Jul 2013 06:35pm EDT
» More General

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Energy +48.59%
Basic Materials +148.72%
Industrials +66.08%
Cyclical Goods & Services +67.38%
Non-Cyclical Goods & Services +59.95%
Financials +72.05%
Healthcare +40.17%
Technology +16.35%
Telecoms +115.35%
Utilities +68.47%

Market News

» More News

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

» View All Earnings Announcements

Analyst Research

Report Title Price
BYOTROL - STILL BUILDING
Provider: Edison Investment Research
$10.00
Buy
BYOTROL - CONSUMER MOVES
Provider: Edison Investment Research
$10.00
Buy
SUMMIT CORPORATION - SERVICE EXPANSION
Provider: Edison Investment Research
$10.00
Buy
LIPOXEN - TRIAL PLANS CONFIRMED
Provider: Edison Investment Research
$10.00
Buy
BYOTROL - REVENUES SHORT OF TARGETS
Provider: Edison Investment Research
$10.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.